DelveInsight’s “Postpartum Depression Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Postpartum Depression, historical and forecasted epidemiology as well as the Postpartum Depression market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Postpartum Depression market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Postpartum Depression market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Postpartum Depression Market Insights
Postpartum Depression Overview
Postpartum depression (PPD) is the most common non-psychotic, complication of childbearing affecting approximately 10-15% of women and as such, represents a considerable public health problem affecting women and their families. The postnatal period is well established as an increased time of risk for the development of serious mood disorders.
Some of the key facts of the Postpartum Depression Market Report:
- The Postpartum Depression market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- In 2022, the total diagnosed prevalent cases of PPD in mothers in the 7MM were ~1,169,000 and these cases are anticipated to increase during the forecast period
- In 2022, among the EU4 countries, France accounted for the highest number of total diagnosed prevalent cases of Postpartum Depression in mothers which accounted for ~32% of the cases in EU4
- Among the 7MM countries, Japan accounted for ~10% of the total diagnosed prevalent cases of Postpartum Depression in mothers in 2022. These cases are further expected to increase during the forecast period
- According to Postpartum Depression organization the reported rate of some type of clinical postpartum depression among new mothers is 10% to 20%
- Key Postpartum Depression Companies: SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, and others
- Key Postpartum Depression Therapies: Zuranolone(SAGE-217), BRII-296, RE104, and others
- The Postpartum Depression epidemiology based on gender analyzed that Postpartum Depression majorly affects females but a small proportion of males can also experience depression post-pregnancy
Get a Free sample for the Postpartum Depression Market Report –
https://www.delveinsight.com/sample-request/postpartum-depression-market
Key benefits of the Postpartum Depression Market report:
- Postpartum Depression market report covers a descriptive overview and comprehensive insight of the Postpartum Depression Epidemiology and Postpartum Depression market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Postpartum Depression market report provides insights on the current and emerging therapies.
- Postpartum Depression market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Postpartum Depression market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Postpartum Depression market.
Download the report to understand which factors are driving Postpartum Depression epidemiology trends @ Postpartum Depression Epidemiological Insights
Postpartum Depression Market
The dynamics of the Postpartum Depression market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
“Despite a tremendous rise in antidepressant prescriptions, still, there is minimal knowledge regarding the trends in the prescription of these drugs by psychiatrists and non-psychiatric specialists. One aspect of ZULRESSO that has affected its after-launch market capturing is its administration pattern, which is a 60 h prolonged intravenous infusion.”
Postpartum Depression Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Postpartum Depression Epidemiology Segmentation:
The Postpartum Depression market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Postpartum Depression
- Prevalent Cases of Postpartum Depression by severity
- Gender-specific Prevalence of Postpartum Depression
- Diagnosed Cases of Episodic and Chronic Postpartum Depression
Postpartum Depression Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Postpartum Depression market or expected to get launched during the study period. The analysis covers Postpartum Depression market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Postpartum Depression Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major Postpartum Depression market share @ Postpartum Depression market forecast
Postpartum Depression Therapies and Key Companies
- Zuranolone(SAGE-217): SAGE Therapeutics
- BRII-296: Brii Biosciences Limited
- RE104: Reunion Neuroscience
Postpartum Depression Market Strengths
- ZULRESSO starts working within 2–3 days of the administration, drastically improving the response rates compared to conventional therapies
- Therapies like BRII-296 and LPCN-1154 are in early stages of clinical development and their approval in future can help the Postpartum Depression therapeutic market grow tremendously
Scope of the Postpartum Depression Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Postpartum Depression Companies: SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, and others
- Key Postpartum Depression Therapies: Zuranolone(SAGE-217), BRII-296, RE104, and others
- Postpartum Depression Therapeutic Assessment: Postpartum Depression current marketed and Postpartum Depression emerging therapies
- Postpartum Depression Market Dynamics: Postpartum Depression market drivers and Postpartum Depression market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Postpartum Depression Unmet Needs, KOL’s views, Analyst’s views, Postpartum Depression Market Access and Reimbursement
Postpartum Depression Market Barriers
- Limited therapies are available for treating and diagnosing Postpartum Depression, thus providing profitable opportunities for emerging therapies
- Increasing research and development to establish the pathophysiology and recent advancement in the diagnosis gives a lucrative opportunity for the Postpartum Depression market
Table of Contents
1. Postpartum Depression Market Report Introduction
2. Executive Summary for Postpartum Depression
3. SWOT analysis of Postpartum Depression
4. Postpartum Depression Patient Share (%) Overview at a Glance
5. Postpartum Depression Market Overview at a Glance
6. Postpartum Depression Disease Background and Overview
7. Postpartum Depression Epidemiology and Patient Population
8. Country-Specific Patient Population of Postpartum Depression
9. Postpartum Depression Current Treatment and Medical Practices
10. Postpartum Depression Unmet Needs
11. Postpartum Depression Emerging Therapies
12. Postpartum Depression Market Outlook
13. Country-Wise Postpartum Depression Market Analysis (2019–2032)
14. Postpartum Depression Market Access and Reimbursement of Therapies
15. Postpartum Depression Market Drivers
16. Postpartum Depression Market Barriers
17. Postpartum Depression Appendix
18. Postpartum Depression Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Postpartum Depression treatment, visit @ Postpartum Depression Medications
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services